Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response

Scandinavian Journal of Immunology

Volumn 74, Issue 3, 2011, Pages 272-281

  Andersen, G N ^a,b   Nilsson, K ^b   Nagaeva, O ^b   Rantapaa Dahlqvist S ^b   Sandstrom T ^b   Mincheva Nilsson, L ^b  

^a AALBORG UNIVERSITY   (Denmark)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MESSENGER RNA;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS; LUNG LAVAGE; MACROPHAGE; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; ANTIGENS, CD3; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LYMPHOTOXIN-ALPHA; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES, REGULATORY;

EID: 79961103319     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02567.x     Document Type: Article

References (40)

1. Famularo G, Giacomelli R, Alesse E et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989;29:59-63.
2. Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
3. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin-4. J Clin Invest 1992;90:1479-85.
4. Duncan MR, Berman B. Stimulation of collagen and glycosaminglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-92.
5. Yamamoto T, Eckes B, Krieg T. Effect of interleukin-10 on the gene expression of type I collagen, fibronectin, and decorin in human skin fibroblasts: differential regulation by transforming growth factor-beta and monocyte chemoattractant protein-1. Biochem Biophys Res Commun 2001;281:200-5.
6. Hashimoto T, Nakamura M, Oshika Y et al. Interleukin-10 relieves the inhibitory effects of interferon-gamma on normal human lung fibroblasts. Int J Mol Med 2001;7:149-54.
7. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997;24:328-32.
8. Giacomelli R, Cipriani P, Lattanzio R et al. Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease. Clin Exp Immunol 1997;108:42-6.
9. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6.
10. Valentini G, Baroni A, Esposito K et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001;21:210-7.
11. Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 1997;40:540-50.
12. Majumdar S, Li D, Ansari T et al. Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies. Eur Respir J 1999;14:251-7.
13. + lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78.
14. Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol 1996;23:654-8.
15. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
16. LeRoy EC, Black C, Fleishmajer R et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
17. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989;16:328-34.
18. 2 on the airways of healthy subjects. Am J Respir Crit Care Med 1997;156:418-24.
19. Nagaeva O, Jonsson L, Mincheva-Nilsson L. Dominant IL-10 and TGF-beta mRNA expression in gammadeltaT cells of human early pregnancy decidua suggests immunoregulatory potential. Am J Reprod Immunol 2002;48:9-17.
20. Andersen GN, Hägglund M, Nagaeva O et al. Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes. Scand J Immunol 2005;61:279-84.
21. Silman A, Harrison M, Brennan P. Is it possible to reduce observer variability in skin score assessment of scleroderma? The ad hoc International Group on the Assessment of Disease Outcome in Scleroderma J Rheumatol 1995;22:1277-80.
22. Andersen GN, Nilsson K, Pourazar J et al. Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007;101:2199-206.
23. Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F. Thymic regulatory cells. Autoimmun Rev 2005;4:579-86.
24. Slobodin G, Ahmad MS, Rosner I et al. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010;261:77-80.
25. Rousset F, Garcia E, Defrance T et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-3.
26. Beretta L, Cappiello F, Barili M, Scorza R. Proximal interleukin-10 gene polymorphisms in Italien patients with systemic sclerosis. Tissue Antigens 2007;69:305-12.
27. Ates Ö, Müsellim B, Öngen G, Topal-Sarikaya A. Association between 'interleukin' 10 gene (IL-10) polymorphisms and systemic sclerosis with interstitial lung involvement. Rheumatol Int 2008;28:1123-6.
28. Hikami K, Ehara Y, Hasegawa M et al. Association of IL-10 receptor 2 (IL10RB) SNP with systemic sclerosis. Biochem Biophys Res Commun 2008;373:403-7.
29. Thompson-Snipes L, Dhar V, Bond MW, Mosmann TR, Moore KW, Rennick DM. Interleukin 10: a novel stimulatory factor for mast cells and their progenitors. J Exp Med 1991;173:507-10.
30. Crestani B, Seta N, De Bandt M et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994;149:1260-5.
31. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999;38:612-7.
32. Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 2002;39:531-6.
33. Sfrent-Cornateanu R, Mihai C, Balan S, Ionescu R, Moldoveanu E. The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006;10:955-9.
34. Molteni M, Della Bella S, Mascagni B et al. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 1999;116:164-8.
35. Hussein MR, Hassan HI, Hofny ER et al. Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol 2005;58:178-84.
36. Beretta L, Bertolotti F, Cappiello F et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis with severe restrictive lung physiology. Hum Immunol 2007;68:603-9.
37. Mincheva-Nilsson L. Pregnancy and gamma/delta T cells: taking on the hard questions. Reprod Biol Endocrinol 2003;1:120.
38. Duan H, Fleming J, Pritchard DK et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008;58:1465-74.
39. Chaudhuri N, Sabroe I. Basic science of the innate immune system and the lung. Paediatr Respir Rev 2008;9:236-42.
40. Baraut J, Michel L, Verrecchia F, Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010;10:65-73.